Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
about
Leveraging big data to transform target selection and drug discoveryIdentification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new eraCDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerMolecular predictive markers in tumors of the gastrointestinal tractColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerProspective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patientsA Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon CancerCurrent status of gene expression profiling to assist decision making in stage II colon cancerPersonalizing health care: feasibility and future implications.Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis.A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer.Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.Colorectal Cancer: Personalized Therapy.Validation of a quantitative 12-multigene expression assay (Oncotype DX(®) Colon Cancer Assay) in Korean patients with stage II colon cancer: implication of ethnic differences contributing to differences in gene expression.ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients.Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche.Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer.Building personalized treatment plans for early-stage colorectal cancer patients.Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria.Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization.A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Development of sulfadiazine-decorated PLGA nanoparticles loaded with 5-fluorouracil and cell viability.Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer.Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer.Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?Intrinsic cancer subtypes-next steps into personalized medicine
P2860
Q26776403-B83003C7-9DD3-4635-A30E-8A9C6AAF2453Q27693248-0F907CCA-DE8B-47F8-9AB4-10587825AFF3Q27853326-6BB0FF19-D5C2-4DF3-BECB-3A0822BE6D6BQ28070583-E8D4A3F4-03F0-402A-A888-5A7A2AD7C1C1Q30238915-37FC21CC-74A4-4AB6-943E-43D2EA2DFFA4Q33577862-C409B5F2-D7A3-4E0F-9EA1-9BABF4203E07Q33776664-A3B06B57-6D2E-41FC-9310-3FC9518961F6Q33829763-AA4B1F32-E2BD-4D2B-96C3-5BC329512977Q34938911-7E874A69-5632-4410-A2EF-4E158D9AF02EQ36027048-7DDDF9B8-B249-4C9B-B34A-107D13AA29B9Q36055744-269412BD-6136-4BBC-BD85-9C44FB71C582Q36068850-0C5FF6BE-3680-4354-9100-12CF0A09233EQ36344547-22FCA607-77D5-4BF5-B6FC-E176ADEBA8E9Q36399053-82E38009-9F6B-4EE7-91C5-E9CE9BD48086Q36691267-03288B57-27E7-4649-BF0A-539EDFCFF3D3Q36729538-EF19CCF4-F16F-4085-A9CB-D0814C3ADF49Q37125051-B875367E-428D-4832-AB48-DA12217699D9Q37706705-D9720878-1E38-4DAD-A6A5-E967AA05C736Q38225744-06676F84-02C4-43CE-897A-655F79D49C4EQ38265382-4F023369-44CA-4F1E-8687-346172711383Q38391639-E3D886CC-C879-448F-89B0-18A9C0F835F5Q38555225-3A5D520D-405B-4C7B-A071-793F12A80795Q38565991-B4588D65-FE27-488F-AB08-8CF021E4F992Q38632574-244E0582-2654-49FC-9B4A-D8E7153D4334Q38647048-996AD42E-2479-4B18-8CED-E5B2BDA22596Q38786707-D818EB38-333A-4BAD-B815-283F24FE774AQ38838757-0BFFF83B-F82E-45A1-9D9D-416B12E94130Q38920845-F65147EF-6AA9-46D8-9EBA-854B03F7D557Q38943220-6834C94E-C282-41FB-A034-497356D826E6Q39180723-A954AA78-EAF0-4A56-BA03-E1DE96D7A3F0Q39306576-6DA76D42-A2D0-4BFA-A9A0-DBCF8B195E91Q40312006-1785256E-74F9-4C00-9397-D39B33C0E55AQ41485067-D6EE282A-AA29-427D-A21B-89A5AD1C3F5AQ44641112-80C1DDF6-2C4E-4FFE-A82B-DD300E5FDD42Q47110810-3DA9E2C9-9AB0-4B73-9F2C-3930A4A4854FQ50489243-CF6DC084-B965-4E6D-B3D3-434C316702EEQ50596135-573F6687-4729-471B-A671-A66520F16008Q53028836-C670F9E3-07FC-475C-88AD-0FD516EF5545Q58053523-E31F219C-83E6-44CC-B9E1-9D6F8F84895BQ58053534-CA61AC82-5C37-42F8-A11F-2AE90A1014D1
P2860
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Validation of the 12-gene colo ...... V) and FU/LV plus oxaliplatin.
@en
Validation of the 12-gene colo ...... th fluorouracil and leucovorin
@nl
type
label
Validation of the 12-gene colo ...... V) and FU/LV plus oxaliplatin.
@en
Validation of the 12-gene colo ...... th fluorouracil and leucovorin
@nl
prefLabel
Validation of the 12-gene colo ...... V) and FU/LV plus oxaliplatin.
@en
Validation of the 12-gene colo ...... th fluorouracil and leucovorin
@nl
P2093
P2860
P356
P1476
Validation of the 12-gene colo ...... LV) and FU/LV plus oxaliplatin
@en
P2093
Carl Millward
Kim M Clark-Langone
Margarita Lopatin
Michael J O'Connell
Norman Wolmark
Saima Sharif
Soonmyung Paik
Steven Shak
P2860
P304
P356
10.1200/JCO.2012.47.3116
P407
P50
P577
2013-11-12T00:00:00Z